Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs

Klaus Weber, Ulrich Mengs, Tobias Schwarz, T. Hajtó, Katarina Hostanska, Thomas R. Allen, Roland Weyhenmeyer, Hans Lentzen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The immune response-modifying drug Lektinol® is a mistletoe preparation which is standardized with respect to bioactive viscum album agglutinin, the most active component of mistletoe. The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. The standardized mistletoe extract was administered intravenously in doses of 100, 1000 or 5000 μl/kg (equivalent to 3, 30 or 150 ng/kg of riscurn album agglutinin) once daily for three weeks. An inhibition of mean pulmonary metastatic colonization of 58 to 95%, as measured by the number of melanoma cells on lung tissue slides, and a significant decrease of percentage of bronchoalveolar lavage pigmented cells were observed. In addition, a correlation of this antirectastatic activity with cellular immune parameters was investigated. In lavage fluids from the tumor-bearing mice, there was a 5 to 6-fold significant increase in the percentage of MAC-1+ (CD11b/CD18) immunocompetent macrophages in comparison with cells from vehicle-treated animals. The percentages of double-positive immature CD4+8+ thymocytes were significantly increased in animals treated with the standardized mistletoe extract. There were no signs of treatment- related toxicity. The results of this study indicate that the standardized mistletoe extract shows antimetastatic activity against B16 melanoma lung colonization.

Original languageEnglish
Pages (from-to)497-502
Number of pages6
JournalArzneimittel-Forschung
Volume48
Issue number5
Publication statusPublished - 1998

Fingerprint

Mistletoe
Experimental Melanomas
Agglutinins
Animals
Bearings (structural)
Lung
Macrophages
Toxicity
Tumors
Tissue
Viscum album
Fluids
Pharmaceutical Preparations
Therapeutic Irrigation
Bronchoalveolar Lavage
Thymocytes
Intravenous Injections
Melanoma
Cell Count
Neoplasms

Keywords

  • B16 melanoma
  • Cancer immunotherapy
  • Lektinol®
  • Metastasis
  • Mistletoe extract
  • Mouse
  • Phytotherapy
  • Viscum album agglutinin

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

Weber, K., Mengs, U., Schwarz, T., Hajtó, T., Hostanska, K., Allen, T. R., ... Lentzen, H. (1998). Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. Arzneimittel-Forschung, 48(5), 497-502.

Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. / Weber, Klaus; Mengs, Ulrich; Schwarz, Tobias; Hajtó, T.; Hostanska, Katarina; Allen, Thomas R.; Weyhenmeyer, Roland; Lentzen, Hans.

In: Arzneimittel-Forschung, Vol. 48, No. 5, 1998, p. 497-502.

Research output: Contribution to journalArticle

Weber, K, Mengs, U, Schwarz, T, Hajtó, T, Hostanska, K, Allen, TR, Weyhenmeyer, R & Lentzen, H 1998, 'Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs', Arzneimittel-Forschung, vol. 48, no. 5, pp. 497-502.
Weber, Klaus ; Mengs, Ulrich ; Schwarz, Tobias ; Hajtó, T. ; Hostanska, Katarina ; Allen, Thomas R. ; Weyhenmeyer, Roland ; Lentzen, Hans. / Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. In: Arzneimittel-Forschung. 1998 ; Vol. 48, No. 5. pp. 497-502.
@article{bce54dea9a2349bf9751e6a025fe44b8,
title = "Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs",
abstract = "The immune response-modifying drug Lektinol{\circledR} is a mistletoe preparation which is standardized with respect to bioactive viscum album agglutinin, the most active component of mistletoe. The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. The standardized mistletoe extract was administered intravenously in doses of 100, 1000 or 5000 μl/kg (equivalent to 3, 30 or 150 ng/kg of riscurn album agglutinin) once daily for three weeks. An inhibition of mean pulmonary metastatic colonization of 58 to 95{\%}, as measured by the number of melanoma cells on lung tissue slides, and a significant decrease of percentage of bronchoalveolar lavage pigmented cells were observed. In addition, a correlation of this antirectastatic activity with cellular immune parameters was investigated. In lavage fluids from the tumor-bearing mice, there was a 5 to 6-fold significant increase in the percentage of MAC-1+ (CD11b/CD18) immunocompetent macrophages in comparison with cells from vehicle-treated animals. The percentages of double-positive immature CD4+8+ thymocytes were significantly increased in animals treated with the standardized mistletoe extract. There were no signs of treatment- related toxicity. The results of this study indicate that the standardized mistletoe extract shows antimetastatic activity against B16 melanoma lung colonization.",
keywords = "B16 melanoma, Cancer immunotherapy, Lektinol{\circledR}, Metastasis, Mistletoe extract, Mouse, Phytotherapy, Viscum album agglutinin",
author = "Klaus Weber and Ulrich Mengs and Tobias Schwarz and T. Hajt{\'o} and Katarina Hostanska and Allen, {Thomas R.} and Roland Weyhenmeyer and Hans Lentzen",
year = "1998",
language = "English",
volume = "48",
pages = "497--502",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "5",

}

TY - JOUR

T1 - Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs

AU - Weber, Klaus

AU - Mengs, Ulrich

AU - Schwarz, Tobias

AU - Hajtó, T.

AU - Hostanska, Katarina

AU - Allen, Thomas R.

AU - Weyhenmeyer, Roland

AU - Lentzen, Hans

PY - 1998

Y1 - 1998

N2 - The immune response-modifying drug Lektinol® is a mistletoe preparation which is standardized with respect to bioactive viscum album agglutinin, the most active component of mistletoe. The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. The standardized mistletoe extract was administered intravenously in doses of 100, 1000 or 5000 μl/kg (equivalent to 3, 30 or 150 ng/kg of riscurn album agglutinin) once daily for three weeks. An inhibition of mean pulmonary metastatic colonization of 58 to 95%, as measured by the number of melanoma cells on lung tissue slides, and a significant decrease of percentage of bronchoalveolar lavage pigmented cells were observed. In addition, a correlation of this antirectastatic activity with cellular immune parameters was investigated. In lavage fluids from the tumor-bearing mice, there was a 5 to 6-fold significant increase in the percentage of MAC-1+ (CD11b/CD18) immunocompetent macrophages in comparison with cells from vehicle-treated animals. The percentages of double-positive immature CD4+8+ thymocytes were significantly increased in animals treated with the standardized mistletoe extract. There were no signs of treatment- related toxicity. The results of this study indicate that the standardized mistletoe extract shows antimetastatic activity against B16 melanoma lung colonization.

AB - The immune response-modifying drug Lektinol® is a mistletoe preparation which is standardized with respect to bioactive viscum album agglutinin, the most active component of mistletoe. The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. The standardized mistletoe extract was administered intravenously in doses of 100, 1000 or 5000 μl/kg (equivalent to 3, 30 or 150 ng/kg of riscurn album agglutinin) once daily for three weeks. An inhibition of mean pulmonary metastatic colonization of 58 to 95%, as measured by the number of melanoma cells on lung tissue slides, and a significant decrease of percentage of bronchoalveolar lavage pigmented cells were observed. In addition, a correlation of this antirectastatic activity with cellular immune parameters was investigated. In lavage fluids from the tumor-bearing mice, there was a 5 to 6-fold significant increase in the percentage of MAC-1+ (CD11b/CD18) immunocompetent macrophages in comparison with cells from vehicle-treated animals. The percentages of double-positive immature CD4+8+ thymocytes were significantly increased in animals treated with the standardized mistletoe extract. There were no signs of treatment- related toxicity. The results of this study indicate that the standardized mistletoe extract shows antimetastatic activity against B16 melanoma lung colonization.

KW - B16 melanoma

KW - Cancer immunotherapy

KW - Lektinol®

KW - Metastasis

KW - Mistletoe extract

KW - Mouse

KW - Phytotherapy

KW - Viscum album agglutinin

UR - http://www.scopus.com/inward/record.url?scp=0031807897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031807897&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 497

EP - 502

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 5

ER -